(2-甲基-1,3-苯并噁唑-6-基)硼酸 | 866332-15-2

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: (2-甲基-1,3-苯并噁唑-6-基)硼酸
• 英文名称: 2-methyl-benzoxazol-6-boronic acid
• 英文别名: (2-methyl-1,3-benzoxazol-6-yl)boronic acid；(2-methylbenzo[d]oxazol-6-yl)boronic acid
• CAS: 866332-15-2
• 化学式: C₈H₈BNO₃
• mdl: MFCD10697425
• 分子量: 176.967
• InChiKey: MFPJERIVTFQLEG-UHFFFAOYSA-N

物化性质

• 沸点：
  367.7±34.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  66.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  (2-甲基-1,3-苯并噁唑-6-基)硼酸 、 (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-bromo-5-methylpyrazin-2-yl)methanol 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 1.5h， 以19%的产率得到{3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methyl-6-(2-methyl-1,3-benzoxazol-6-yl)pyrazin-2-yl}methanol
  参考文献：
  名称：

  [EN] 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS
  [FR] 3-MÉTHYLPYRAZINES 2,5-DISUBSTITUÉES ET 3-MÉTHYL PYRAZINES 2,5,6-TRISUBSTITUÉS EN TANT QU'INHIBITEURS ALLOSTÉRIQUES DE SHP2

  摘要：

  公开号：

  WO2018013597A4

文献信息

• INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
  申请人：ECKHARDT Matthias

  公开号：US20140148462A1

  公开（公告）日：2014-05-29

  The present invention relates to compounds of general formula I, wherein the group (Het)Ar is defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式I的化合物，其中(Het)Ar基团的定义如权利要求1所述，具有有价值的药理特性，特别是与GPR40受体结合并调节其活性。这些化合物适用于治疗和预防可受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• Indanyloxydihydrobenzofuranylacetic acids
  申请人：Eckhardt Matthias

  公开号：US08815864B2

  公开（公告）日：2014-08-26

  The present invention relates to compounds of general formula I, wherein the group (Het)Ar is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及通式I的化合物，其中（Het）Ar基团如权利要求书1所定义，具有有价值的药理特性，特别是结合到GPR40受体并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy
  作者：Hasane Ratni、Gary M. Karp、Marla Weetall、Nikolai A. Naryshkin、Sergey V. Paushkin、Karen S. Chen、Kathleen D. McCarthy、Hongyan Qi、Anthony Turpoff、Matthew G. Woll、Xiaoyan Zhang、Nanjing Zhang、Tianle Yang、Amal Dakka、Priya Vazirani、Xin Zhao、Emmanuel Pinard、Luke Green、Pascale David-Pierson、Dietrich Tuerck、Agnes Poirier、Wolfgang Muster、Stephan Kirchner、Lutz Mueller、Irene Gerlach、Friedrich Metzger

  DOI：10.1021/acs.jmedchem.6b00459

  日期：2016.7.14

  Spinal muscular atrophy (SMA) is the leading genetic cause of infant and toddler mortality, and there is currently no approved therapy available. SMA is caused by mutation or deletion of the survival motor neuron 1 (SMN1) gene. These mutations or deletions result in low levels of functional SMN protein. SMN2, a paralogous gene to SMN1, undergoes alternative splicing and exclusion of exon 7, producing an unstable, truncated SMI\T07 protein. Herein, we report the identification of a pyridopyrimidinone series of small molecules that modify the alternative splicing of SMN2, increasing the production of fulllength SMN2 mRNA. Upon oral administration of our small molecules, the levels of fulllength SMN protein were restored in two mouse models of SMA. In-depth lead optimization in the pyridopyrimidinone series culminated in the selection of compound 3 (RG7800), the first small molecule SMN2 splicing modifier to enter human clinical trials.
• [EN] 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS<br/>[FR] 3-MÉTHYLPYRAZINES 2,5-DISUBSTITUÉES ET 3-MÉTHYL PYRAZINES 2,5,6-TRISUBSTITUÉS EN TANT QU'INHIBITEURS ALLOSTÉRIQUES DE SHP2
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2018013597A4

  公开（公告）日：2018-04-05